Dr. David Sinclair on the Next Frontier: Reprogramming Cells to Reverse Biological Age

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.

In a wide-ranging conversation, the Harvard geneticist discusses new epigenetic reprogramming therapies, why he believes aging is a disease we can treat, and the clinical trials that could change everything.